Additionally, in NSCLC cell lines, overexpression of HER-2/neu has been reported to be associated with resistance to chemotherapeutic agents (Tsai et al, 1993) and a synergistic effect was obtained when trastuzumab was combined with chemotherapeutic agents (Bunn et al, 2001). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.